Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers

被引：28

作者：

Peeters, Marc ^{[1
]}

Cervantes, Andres ^{[2
]}

Vera, Shanti Moreno ^{[3
]}

Taieb, Julien ^{[4
]}

机构：

[1] Antwerp Univ Hosp, Edegem, Belgium

[2] Univ Valencia, Biomed Res Inst INCLIVA, Dept Med Oncol, CIBERONC, Blasco Ibanez 17, Valencia 46010, Spain

[3] Servier, Global Med Affairs, Oncol, Suresnes, France

[4] Paris Descartes Univ, HEGP, AP HP, Sorbonne Paris Cite, F-75015 Paris, France

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 16期

关键词：

colorectal cancer; gastrointestinal cancer; trifluridine/tipiracil; METASTATIC COLORECTAL-CANCER; ORAL CHEMOTHERAPEUTIC-AGENT; CLINICAL-PRACTICE GUIDELINES; FOLFIRI PLUS BEVACIZUMAB; GASTRIC-CANCER; TAS-102; MONOTHERAPY; OPEN-LABEL; SYNERGISTIC INTERACTION; INDUCED CYTOTOXICITY; 1ST-LINE TREATMENT;

D O I：

10.2217/fon-2018-0147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fluoropyrimidines are currently the backbone of treatment for gastrointestinal (GI) cancers but development of resistance to these agents remains a major problem. Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer. This article reviews the clinical value of trifluridine/tipiracil as a monotherapy, including recent trials in GI cancers, and the potential benefit of combining it with other agents in patients with GI cancers, including the preclinical rationale for combination therapy and recently completed and ongoing clinical trials. Data gathered so far suggest that trifluridine/tipiracil has the potential to form the chemotherapeutic backbone in the continuum of care for GI cancers in the future.

引用

页码：1629 / 1645

页数：17

共 62 条

[1] Gastric Cancer, Version 3.2016 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Almhanna, Khaldoun ;

Bentrem, David J. ;

Chao, Joseph ;

Das, Prajnan ;

Denlinger, Crystal S. ;

Fanta, Paul ;

Farjah, Farhood ;

Fuchs, Charles S. ;

Gerdes, Hans ;

Gibson, Michael ;

Glasgow, Robert E. ;

Hayman, James A. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Jaroszewski, Dawn ;

Johung, Kimberly L. ;

Keswani, Rajesh N. ;

Kleinberg, Lawrence R. ;

Korn, W. Michael ;

Leong, Stephen ;

Linn, Catherine ;

Lockhart, A. Craig ;

Ly, Quan P. ;

Mulcahy, Mary F. ;

Orringer, Mark B. ;

Perry, Kyle A. ;

Poultsides, George A. ;

Scott, Walter J. ;

Strong, Vivian E. ;

Washington, Mary Kay ;

Weksler, Benny ;

Willett, Christopher G. ;

Wright, Cameron D. ;

Zelman, Debra ;

McMillian, Nicole ;

Sundar, Hema .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10) :1286-1312

[2]

Alcindor T, 2011, CURR ONCOL, V18, P18

[3]

[Anonymous], J CLIN ONCOL S

[4]

[Anonymous], ANN ONCOL S3

[5]

[Anonymous], ESMO 19 WORLD C GAST

[6]

[Anonymous], J CLIN ONCOL S

[7]

[Anonymous], J CIN ONCOL

[8] Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Van Cutsem, E. ;

Cervantes, A. ;

Nordlinger, B. ;

Arnold, D. .

ANNALS OF ONCOLOGY, 2014, 25 :1-9

[9]

[Anonymous], ANN ONCOL

[10] Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine [J].

Baba, Yuji ;

Tamura, Toshiya ;

Satoh, Yoshihiko ;

Gotou, Masamitsu ;

Sawada, Hiroshi ;

Ebara, Shunsuke ;

Shibuya, Kazunori ;

Soeda, Jumpei ;

Nakamura, Kazuhide .

MOLECULAR ONCOLOGY, 2017, 11 (08) :1065-1077

← 1 2 3 4 5 6 7 →